In 2003 Boehringer Ingelheim and Abbott Laboratories announced a cooperative arrangement that will help prevent the transmission of HIV from mother to child in the developing world through their respective donation programs. Through this arrangement, organizations can receive Abbott's Determine® HIV rapid tests and Viramune® (nevirapine), an antiretroviral drug developed by Boehringer-Ingelheim. In addition to providing tests and treatment, the two companies are committed to provide greater access to these donated products while making it easier for organizations to receive the donated products and encouraging the creation of new PMTCT programs in developing countries. Any organization that provides testing and treatment for PMTCT through a sound and sustainable program of care may request a donation of Determine® HIV through Axios International who administers the application process for both programs. A common web site has also been established to simplify the process by which PMTCT programs obtain free HIV tests and Viramune® (nevirapine).

Abbott Laboratories, Boehringer Ingelheim and WHO recognize the potential for PMTCT sites to serve as a natural entry point for providing access to chronic treatment. Functioning PMTCT sites catalyze the improvement of infrastructure and access to health care in resource poor settings. This is primarily due to the multi-disciplinary approach required for a successful program.